Rhythm Pharmaceuticals (RYTM) Competitors

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, community ranking, earnings and analyst recommendations.

Does the media prefer RYTM or GMAB?

In the previous week, Genmab A/S had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 4 mentions for Genmab A/S and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.70 beat Genmab A/S's score of 0.68 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Is RYTM or GMAB more profitable?

Genmab A/S has a net margin of 23.49% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Genmab A/S's return on equity of 14.64% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-230.07%	-367.36%	-77.47%
Genmab A/S	23.49%	14.64%	12.37%

Which has stronger valuation and earnings, RYTM or GMAB?

Genmab A/S has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$112.53M	31.02	-$184.68M	-$4.33	-13.12
Genmab A/S	$19.84B	0.67	$631.91M	$1.03	19.45

Do insiders & institutionals believe in RYTM or GMAB?

7.1% of Genmab A/S shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in RYTM or GMAB?

Rhythm Pharmaceuticals received 132 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 66.82% of users gave Rhythm Pharmaceuticals an outperform vote while only 62.75% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Rhythm Pharmaceuticals	Outperform Votes 292 66.82%	Underperform Votes 145 33.18%
Genmab A/S	Outperform Votes 160 62.75%	Underperform Votes 95 37.25%

Do analysts prefer RYTM or GMAB?

Rhythm Pharmaceuticals currently has a consensus price target of $63.70, indicating a potential upside of 12.15%. Genmab A/S has a consensus price target of $45.20, indicating a potential upside of 125.66%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Which has more volatility and risk, RYTM or GMAB?

Rhythm Pharmaceuticals has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

Genmab A/S beats Rhythm Pharmaceuticals on 10 of the 18 factors compared between the two stocks.